Abstract
The objective of this study was to determine the association between the patterns of change in the dopaminergic metabolite plasma homovanillic acid (HVA), the noradrenergic metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG), and psychosis following haloperidol withdrawal in schizophrenic patients. Weekly plasma measurements were obtained in 107 subjects with schizophrenia or schizoaffective disorder. Random regression was used to control for individual variance while modeling metabolite changes over time and relationships with psychosis. Changes in plasma MHPG were not significantly associated with relapse or psychosis, while increased plasma HVA was found to be associated with relapse. Psychosis was correlated negatively with plasma HVA levels. The current analysis, controlling for individual variance, indicates that there is evidence for pharmacological effects on plasma HVA, but not plasma MHPG. In addition, these metabolites do not appear to be direct markers of psychosis, but may be associated with a compensatory response by the system to return to the steady state.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
American Psychiatric Association . (1987): Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., Revised. Washington, DC, American Psychiatric Association
Amin F, Davidson M, Davis KL . (1992): Homovanillic acid measurement in clinical research: A review of methodology. Schizophr Bull 18: 123–148
Amin F, Siever LJ, Silverman J, Coccaro EF, Mitropoulou V, Trestman RL, Anderson GM, Davis KL . (1997): Plasma HVA in schizotypal personality disorder. In Friedhoff AJ, Amin F (eds), Plasma Homovanillic Acid in Schizophrenia: Implications for Presynaptic Dopamine Dysfunction. Washington, DC, APA Press, pp 133–149
Antelman SM, Caggiula AR . (1977): Norepinephrine-dopamine interactions and behavior. Science 195: 646–653
Bacopoulos NG, Hattox SE, Roth RH . (1979): 3,4-dihydroxyphenylacetic acid and homovanillic acid in rat plasma: Possible indicators of central dopaminergic activity. Eur J Pharmacology 56: 225–236
Beuger M, van Kammen DP, Kelley ME, Yao J . (1996): Dopamine turnover in schizophrenia before and after haloperidol withdrawal: CSF, plasma and urine studies. Neuropsychopharmacology 15: 75–86
Bleuler E . (1911): Dementia Praecox or the Group of Schizophrenias. Zinkin J (trans) (1950). New York, International University Press
Bowers MB Jr, Swigar ME, Jatlow PI, Hoffman F, Giocoechea N . (1986): Early neuroleptic response in psychotic men and women: Correlation with plasma HVA and MHPG. Comprehensive Psychiatry 27: 181–185
Bowers MB Jr, Swigar ME, Jatlow PI, Goicoechea N . (1984): Plasma catecholamine metabolites and early response to haloperidol. J Clin Psychiatry 45: 248–251
Bunney WE Jr, Hamburg DA . (1963): Methods for reliable longitudinal observation of behavior. Arch Gen Psychiatry 9: 280–294
Chang W-H, Chen T-Y, Lin S-K, Lung F-W, Lin W-L, Hu W-H, Yeh E-K . (1990): Plasma catecholamine metabolites in schizophrenics: Evidence for the two-subtype concept. Biol Psychiatry 27: 510–518
Chang W-H, Chen T-Y, Lee C-F, Hung J-C, Hu W-H, Yeh E-K . (1988): Plasma homovanillic acid levels and subtyping of schizophrenia. Psychiatry Res 23: 239–244
Davidson M, Losonczy MF, Mohs RC, Lesser JC, Powchik P, Freed LB, Davis BM, Mykytyn VV, Davis KL . (1987a): Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients. Neuropsychopharmacology 1: 17–23
Davidson M, Giordani AB, Mohs RC, Mykytyn VV, Platt S, Aryan ZS, Davis KL . (1987b): Control of exogenous factors affecting plasma homovanillic acid concentration. Psychiatry Res 20: 307–312
Davidson M, Davis KL . (1988): A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Arch Gen Psychiatry 45: 561–563
Davidson M, Kahn RS, Knott P, Kaminsky R, Cooper M, DuMont K, Apter S, Davis KL . (1991a): Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Arch Gen Psychiatry 48: 910–913
Davidson M, Kahn RS, Powchik P, Warne P, Losonczy MF, Kaminsky R, Apter S, Jaff S, Davis KL . (1991b): Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch Gen Psychiatry 48: 73–76
Davila R, Manero E, Zumarraga M, Andia I, Schweitzer JW, Friedhoff AJ . (1988): Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatry 45: 564–567
Davila R, Gonzalez MA, Zumarraga M, Andia I, Guimon J, Silva RR, Friedhoff AJ . (1995): Plasma prolactin and plasma homovanillic acid: Predictors of clinical response in schizophrenia. Biol Psychiatry 38: 267–269
Duncan E, Wolkin A, Angrist B, Sanfilipo M, Wieland S, Cooper TB, Rotrosen J . (1993): Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics. Biol Psychiatry 34: 523–528
Friedhoff AJ . (1986): A dopamine-dependent restitutive system for the maintenance of mental normalcy. Ann NY Acad Sci 463: 47–52
Friedhoff AJ, Carr KD, Uysal S, Schweitzer J . (1995): Repeated inescapable stress produces a neuroleptic like effect on the conditioned avoidance response. Neuropsychopharmacology 13: 129–138
Gerhardt GA, Drebing CJ, Freedman R . (1986): Simultaneous determination of free homovanillic acid, (3-methoxy-4-hydroxypheynl)ethylene glycol, and vanilmandelic acid in human plasma by high-performance liquid chromatography coupled with dual-electrode coulometric electrochemical detection. Anal Chem 58: 2879–2883
Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, Shea MT, Imber SD, Sotsky SM, Watkins JT . (1993): Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Arch Gen Psychiatry 50: 739–750
Glazer WM, Bowers MB Jr, Charney DS, Heninger GR . (1989): The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia. Biol Psychiatry 26: 224–233
Green Al, Alam MY, Boshes RA, Waternaux C, Pappalardo KM, Fitzgibbon ME, Tsuang MT, Schildkraut JJ . (1993): Haloperidol response and plasma catecholamines and their metabolites. Schizophr Res 10: 33–37
Hornykiewicz O . (1982): Brain catecholamines in schizophrenia—a good case for noradrenaline. Nature 299: 484–486
Javaid JI, Sharma RP, Janicak PG, Davis JM . (1990): Plasma HVA in psychiatric patients: Longitudinal studies. Psychopharmacol Bull 26: 361–365
Kendler KS, Hsieh JY-K, Davis KL . (1982): Studies of plasma homovanillic acid as an index of brain dopamine function. Psychopharmacol Bull 18: 152–155
Kirch DG, Jaskiw G, Linnoila M, Weinberger DR, Wyatt RJ . (1988): Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients. Psychiatry Res 25: 233–242
Kirch D, Hattox S, Bell J, Murphy R, Freedman R . (1983): Plasma homovanillic acid and tardive dyskinesia during neuroleptic maintenance and withdrawal. Psychiatry Res 9: 217–223
Ko GN, Jimerson DC, Wyatt RJ, Bigelow LB . (1988): Plasma 3-methoxy-4-hydroxyphenylglycol changes associated with clinical state and schizophrenic subtype. Arch Gen Psychiatry 45: 842–846
Kopin IJ, Bankiewicz KS, Harvey-White J . (1988): Assessment of brain dopamine metabolism from plasma HVA and MHPG during debrisoquin treatment: Validation in monkeys treated with MPTP. Neuropsychopharmacology 1: 119–125
Koreen AR, Lieberman J, Alvir J, Mayerhoff D, Loebel A, Chakos M, Amin F, Cooper T . (1994): Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response. Arch Gen Psychiatry 51: 132–138
Labarca R, Silva H, Jerez S, Ruiz A, Forray MI, Gysling K, Andres ME, Bustos G, Castillo T, Hono J . (1993): Differential effects of haloperidol on negative symptoms in drug-naive schizophrenic patients: Effects on plasma homovanillic acid. Schizophr Res 9: 29–34
Laird NM, Ware JH . (1982): Random-effects models of longitudinal data. Biometrics 38: 963–974
Laird NM . (1988): Missing data in longitudinal studies. Stat Med 7: 305–315
Lambert GW, Eisenhofer G, Jennings GL, Esler MD . (1993): Regional homovanillic acid production in humans. Life Sci 53: 63–75
Maas JW, Contreras SA, Seleshi E, Bowden CL . (1988): Dopamine metabolism and disposition in schizophrenic patients. Arch Gen Psychiatry 45: 553–559
Maas JW, Contreras SA, Miller AL, Berman N, Bowden CL, Javors MA, Seleshi E, Weintraub S . (1993): Studies of catecholamine metabolism in schizophrenia/psychosis-I. Neurospsychopharmacology 8: 97–109
Mazure CM, Nelson JC, Jatlow PI, Bowers MB . (1991): Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biol Psychiatry 30: 475–482
Newcomer JW, Riney SJ, Vinogradov S, Csernansky JG . (1992): Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia. Psychiatry Res 41: 191–202
Petrie EC, Faustman WO, Moses JA, Lombrozo L, Csernansky JG . (1990): Correlates of rapid neuroleptic response in male patients with schizophrenia. Psychiatry Res 33: 171–177
Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, Breier A, Linnoila M, Paul SM . (1986): Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry 43: 669–676
Pickar D, Labarca R, Linnoila M, Roy A, Hommer D, Everett D, Paul SM . (1984): Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 225: 954–957
Rieder RO . (1974): The origins of our confusion about schizophrenia. Psychiatry 37: 197–208
SAS Institute Inc . (1992): SAS Technical Report P-229, SAS/STAT Software: Changes and Enhancements, Release 6.07. Cary, NC, SAS Institute Inc.
Scheffer R, Diamond BI, Borison RL, Correnti EE, Mukherjee S . (1994): Low plasma homovanillic acid (HVA) at the onset of psychosis (abstract). Biol Psychiatry 35: 701–702
Sharma RP, Javaid JI, Pandey GN, Janicak PG, Davis JM . (1991): Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients. Biol Psychiatry 30: 459–466
Sharma RP, Javaid JI, Janicak PG, Comaty J, Davis JM . (1989): Plasma and CSF HVA before and after pharmacological treatment. Psychiatr Res 28: 97–104
Siever LJ, Amin F, Coccaro EF, Bernstein D, Kavoussi RJ, Kalus O, Horvath TB, Warne P, Davidson M, Davis KL . (1991): Plasma homovanillic acid in schizotypal personality disorder. Am J Psychiatry 148: 1246–1248
Sumiyoshi T, Hasegawa M, Jayathilake K, Meltzer HY . (1997): Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: Relation to neuroleptic resistance. Biol Psychiatry 41: 560–566
Swann AC, Maas JW, Hattox SE, Landis H . (1980): Catecholamine metabolites in human plasma as indices of brain function: Effects of debrisoquin. Life Sci 27: 1857–1862
van Kammen DP, Kelley M . (1991): Dopamine and norepinephrine activity in schizophrenia: An integrative perspective. Schizophr Res 4: 173–191
van Kammen DP, Peters JL, van Kammen WB, Nugent A, Goetz KL, Yao J, Linnoila M . (1989): CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal. Biol Psychiatry 26: 176–188
van Kammen DP, Ågren H, Yao JK, O'Connor DT, Gurklis JA, Peters JL . (1994): Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. Am J Psychiatry 151: 379–384
van Kammen DP, Kelley ME, Gurklis JA, Gilbertson MW, Yao JK, Peters JL . (1995): Behavioral vs. biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. Arch Gen Psychiatry 52: 673–678
van Kammen DP, Kelley ME, Gurklis JA, Gilbertson MW, Yao JK, Condray R, Peters JL . (1996a): Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patients. Neuropsychopharmacology 14: 275–283
van Kammen DP, Kelley ME, Yao JK, Gilbertson MW, Gurklis JA, Inosaka T, Saito H, Peters JL, Sato M . (1996b): Predicting haloperidol treatment response in chronic schizophrenia. Psychiatry Res 64: 47–58
Van Putten T, Marder SR, Aravagiri M, Chabert N, Mintz J . (1989): Plasma homovanillic acid as a predictor of response to fluphenzine treatment. Psychopharmacol Bull 1: 89–91
Acknowledgements
The authors thank the staff and patients of the Schizophrenia Research and Treatment Unit, VA Pittsburgh Healthcare System, for their support and dedication. Funding for this work was provided by the VA Merit Review Board, NIMH R01 MH-44841, and the Bataan and Corregidor Medical Fund, Inc. Partial theory and data analysis was presented as part of a master's thesis (MK) at the Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kelley, M., Yao, J. & van Kammen, D. Plasma Catecholamine Metabolites as Markers for Psychosis and Antipsychotic Response in Schizophrenia. Neuropsychopharmacol 20, 603–611 (1999). https://doi.org/10.1016/S0893-133X(98)00094-3
Received:
Revised:
Accepted:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(98)00094-3
Keywords
This article is cited by
-
The biochemical womb of schizophrenia: A review
Indian Journal of Clinical Biochemistry (2008)
